Phreesia (NYSE:PHR) Downgraded by Wall Street Zen to Buy

Wall Street Zen downgraded shares of Phreesia (NYSE:PHR) from a strong-buy rating to a buy rating in a research report released on Sunday morning.

Other equities analysts have also issued research reports about the stock. DA Davidson dropped their price target on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Zacks Research downgraded Phreesia from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Canaccord Genuity Group cut their target price on Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, December 9th. JPMorgan Chase & Co. reduced their target price on Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, December 9th. Finally, BMO Capital Markets assumed coverage on Phreesia in a research note on Thursday, November 13th. They set an “outperform” rating and a $32.00 price target for the company. Seventeen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.41.

Phreesia Stock Performance

Phreesia stock opened at $12.22 on Friday. The stock has a fifty day moving average price of $16.40 and a 200 day moving average price of $21.88. Phreesia has a 52 week low of $12.06 and a 52 week high of $32.76. The firm has a market capitalization of $736.74 million, a P/E ratio of -122.19 and a beta of 0.65. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company had revenue of $120.33 million during the quarter, compared to analysts’ expectations of $119.98 million. During the same quarter in the previous year, the business earned ($0.25) EPS. The firm’s revenue was up 12.7% on a year-over-year basis. Equities research analysts anticipate that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity at Phreesia

In related news, SVP Amy Beth Vanduyn sold 2,602 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $44,260.02. Following the transaction, the senior vice president directly owned 160,238 shares of the company’s stock, valued at approximately $2,725,648.38. The trade was a 1.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Evan Roberts sold 6,317 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $107,452.17. Following the completion of the transaction, the insider owned 834,632 shares of the company’s stock, valued at approximately $14,197,090.32. This represents a 0.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 60,766 shares of company stock valued at $1,013,817 over the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

A number of hedge funds have recently made changes to their positions in PHR. Legato Capital Management LLC increased its holdings in Phreesia by 10.1% during the 4th quarter. Legato Capital Management LLC now owns 33,332 shares of the company’s stock worth $564,000 after purchasing an additional 3,054 shares during the last quarter. Mach 1 Financial Group LLC acquired a new stake in shares of Phreesia during the fourth quarter worth approximately $176,000. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Phreesia by 147.1% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 58,030 shares of the company’s stock worth $982,000 after buying an additional 34,550 shares during the last quarter. Schwartz Investment Counsel Inc. increased its stake in shares of Phreesia by 60.6% in the fourth quarter. Schwartz Investment Counsel Inc. now owns 78,700 shares of the company’s stock worth $1,332,000 after buying an additional 29,700 shares during the last quarter. Finally, Nicholas Company Inc. raised its holdings in Phreesia by 17.2% in the fourth quarter. Nicholas Company Inc. now owns 248,652 shares of the company’s stock valued at $4,207,000 after acquiring an additional 36,515 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.